Company Overview

Update
Founded:
2001
Founders:
Christoph Westphal, Ram Sasisekharan
Headquarters:
Cambridge, MA
IPO:
Went Public on Jun 22, 2004
Stock:
MNTA
Categories:
Biotechnology
Description:
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.

Detailed Description

Update

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company’s two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Current Team (5)

Update

Past Team (9)

Update

Board Members and Advisors (3)

Update

Offices/Locations (1)

Update
  • Headquarters

    675 West Kendall Street

    Cambridge, MA 02142

    USA

Images (1)

Update
  • Pu2dy1ipddsmln6v253s